• HHS Secretary Hints at Disruptive Changes; FDA Commissioner Takes Aim at Drug CEO Comments on Social Media; More

    The Department of Justice cleared yet another hurdle for Cigna to acquire PBM Express Scripts. FDA Commissioner Scott Gottlieb took aim at the CEO of a drug company, taking to social media to make add his comments to the ongoing dialogue on high drug costs. All across America, high prescription drug costs - and what ...

  • Copycat Comments and Biosimilars in the News

    Can you trust comments online? Not always, according to the Washington Post, which revealed that among 1,400 comments on proposed cuts to a drug discount program many comments were duplicates or exact copies. A panel examined biosimilars and listened to the public's questions and concerns, and in Washington, Trump's health chief met with GOP lawmakers ...

  • Many Steps Taken to Lower the Cost of Prescription Drugs

    Value-based drug pricing, looser restrictions on Part D drug formularies...it seems as if every group and organization is trying to help patients access and pay for their medications. In this week’s Innovation Partners BioBlog, we’ll take a look at oncology biosimilars, Medicaid value-based drug pricing, and much more. Do Oncology Biosimilars Have a Place in ...

  • The Deal Goes Through – A Look at the Cigna, ExpressScripts Purchase of PBM and More

    This week’s Innovation Partners BioBlog takes a look at several aspects of the business of healthcare. First, the impressive news that the Cigna, Express Scripts deal to acquire PBM was approved by shareholders in both companies, a move that goes against expert predictions. Over 150 medical organizations and groups praise the Trump Administration’s efforts to ...

  • The Costs of Prescription Drugs

    This week’s Innovation Partners BioBlog looks at costs - the cost of prescription drugs. From CVS shifting drug pricing leverage to new data showing hidden costs in Medicare’s prescription drug program, the cost of medication is definitely in the spotlight right now. CVS' move to lean on ICER data could mean dramatic shift in drug ...

  • Advances in the Fight Against Cancer, Drug Prices and More

    This week the FDA approved a new treatment for rare adrenal gland tumors. Researchers at Johns Hopkins made a discovery that could lead to breakthroughs in the fight against cancer, and drug companies are talking openly about drug prices. These top stories and more in this week’s Innovation Partners BioBlog. FDA approves Progenics' treatment for ...

  • Soaring Drug Prices Under Continuing Scrutiny

    Soaring drug prices continue to be under scrutiny this week as our lead story attests. CAR-T therapy offers hope to cancer patients but at what cost to insurers? The Trump Administration continues its offensive against big pharma and drug price increases. These top stories and more in this week’s Innovation Partners BioBlog. Staggering Prices Slow ...

  • Amazon Launches Competitively Priced Drugstore Items, Kymriah Funding Is Cut and More

    This week’s Innovation Partners BioBlog surveys the pharmaceutical world for updates from many different quarters. E-commerce giant Amazon announced it would launch a line of competitively priced over the counter medications while Novartis’ Kyrmiah funding was cut by Medicare/Medicaid after questions arose about influence and payments. This and more in the BioBlog. Amazon undercuts drugstores ...

  • News from the Pharmaceutical Industry, Plus Changes to Medicaid in Effect

    This week’s Innovation Partners Bio Blog features news and updates from Array BioPharma, Merck, Puma, and other pharmaceutical companies in this week’s BioBlog as well as updates on 340B and the new, controversial Medicaid changes, the first such changes in 53 years. Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI®(binimetinib) The ...

  • The Business of Healthcare – News

    The business of healthcare is the top of this week’s Innovation Partners BioBlog. AllianceRx Walgreens selects Inovalon for its new cloud-based specialty pharmacy, and there’s a move afoot to learn from retail giants like Amazon and apply the lessons to health organization management. Meanwhile, states plan to sue the Trump administration over its adjustments to ...